Desenvolvimento de artrite reumática no curso de terapia de gefitinib

Autores

  • Gen Ohara University of Tsukuba
  • Hiroaki Satoh University of Tsukuba
  • Mika Kohno University of Tsukuba
  • Daisuke Goto University of Tsukuba
  • Takayuki Sumida University of Tsukuba
  • Nobuyuki Hizawa University of Tsukuba

Downloads

Não há dados estatísticos.

Biografia do Autor

Gen Ohara, University of Tsukuba

MD. Member of the medical staff, Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan.

Hiroaki Satoh, University of Tsukuba

MD. Professor, Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki, Japan.

Mika Kohno, University of Tsukuba

MD. Member of the medical staff, Division of Rheumatology Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan.

Daisuke Goto, University of Tsukuba

MD. Member of the medical staff, Division of Rheumatology Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan.

Takayuki Sumida, University of Tsukuba

MD. Professor, Division of Rheumatology Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan.

Nobuyuki Hizawa, University of Tsukuba

MD. Professor, Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan.

Referências

del Giglio A, Ito C. Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center. Sao Paulo Med J. 2004;122(3):128-30.

Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.

Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21(12):2237-46.

Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149-58.

Seiverling EV, Fernanadez EM, Adams D. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption. J Drugs Dermatol. 2006;5(4):368-9.

Downloads

Publicado

2009-05-05

Como Citar

1.
Ohara G, Satoh H, Kohno M, Goto D, Sumida T, Hizawa N. Desenvolvimento de artrite reumática no curso de terapia de gefitinib. Sao Paulo Med J [Internet]. 5º de maio de 2009 [citado 14º de março de 2025];127(3):177-8. Disponível em: https://periodicosapm.emnuvens.com.br/spmj/article/view/1866

Edição

v. 127 n. 3 (2009)

Seção

Carta ao Editor

Licença

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.